Lipoprotein lipase 1595 C/G and hepatic lipase -480 C/T polymorphisms - Impact on lipid profile in incident dialysis patients

Blood Purification

Volumn 26, Issue 6, 2008, Pages 555-560

  Chmielewski, Michal ^a,b,d   Stenvinkel, Peter ^a   Luttropp, Karin ^a   Suliman, Mohammed E ^a,c   Qureshi, Abdul R ^a   Carrero, Juan J ^a   Barany, Peter ^a   Heimburger, Olof ^a   Nordfors, Louise ^a   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic kidney disease; Dialysis; Hepatic lipase 480 C T; Lipoprotein lipase 1595 C G; Single nucleotide polymorphism

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DISEASE PREDISPOSITION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, HDL; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; LIPASE; LIPIDS; LIPOPROTEIN LIPASE; POLYMORPHISM, GENETIC; RENAL DIALYSIS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 57049184117     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178772     Document Type: Article

References (18)

1. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262-F272.
2. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
3. Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ, Stroes ES, Kuivenhoven JA: Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006;26:1236-1245.
4. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z: Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004;24:1750-1754.
5. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM: The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 2004;89:3858-3863.
6. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG: Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 2003;41:1972-1982.
7. McCaskie PA, Cadby G, Hung J, McQuillan BM, Chapman CM, Carter KW, Thompson PL, Palmer LJ, Beilby JP: The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. Clin Genet 2006;70:114-121.
8. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
9. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeebhoy KN: What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987;11:8-13.
10. Stern C: The Hardy-Weinberg Law. Science 1943;97:137-138.
11. Chan MK, Persaud J, Varghese Z, Moorhead JF: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984;25:812-818.
12. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG: Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996;97:2167-2173.
13. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD: Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 2003;44:1279-1286.
14. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, Yoshida H: Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int 2003;64:1829-1837.
15. Shoji T, Nishizawa Y: Plasma lipoprotein abnormalities in hemodialysis patients - clinical implications and therapeutic guidelines. Ther Apher Dial 2006;10:305-315.
16. Prichard SS: Management of hyperlipidemia in patients on peritoneal dialysis: current approaches. Kidney Int Suppl 2006:S115-S117.
17. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-2907.
18. Stenvinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003;14:1927-1939.